Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2066 in Adult Participants With Respiratory Syncytial Virus Infection
NCT07881991Phase 2Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYH2066 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Area under the curve of RSV RNA viral load. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SYH2066
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07881991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881991.